Friday, September 28, 2018
Taro Pharmaceutical terminates license agreement with NovaBiotics
Taro Pharmaceutical Industries announced that it has terminated the license agreement with NovaBiotics for the onychomycosis drug, Novexatin. As previously disclosed in May 2018, the Novexatin clinical study did not meet the main goal of a Phase IIb study under current guidelines of the FDA and did not show superiority over the placebo. Upon further analysis and evaluation, the Company has decided to terminate its agreement with NovaBiotics.
https://thefly.com/landingPageNews.php?id=2797335
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.